Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176280 | 0.83 | RAB9A (0.54) | LMNAHTTRAB9AHSPB1ALDH1A1 | |
| SCHEMBL1892428 | 0.79 | MEN1 (0.50) | RAB9AALDH1A1MAPTGAAKDR | |
| SCHEMBL2763413 | 0.78 | HTT (0.50) | LMNAHTTRAB9AHSPB1ALDH1A1 | |
| SCHEMBL3187491 | 0.78 | RAB9A (0.49) | LMNAHTTRAB9AHSPB1ALDH1A1 | |
| SCHEMBL1888125 | 0.78 | MEN1 (0.68) | LMNAHTTRAB9AHSPB1ALDH1A1 | |
| SCHEMBL12813013 | 0.77 | ALDH1A1 (0.55) | ROCK1HTTALDH1A1CA1CA2 | |
| SCHEMBL23323402 | 0.76 | RAB9A (0.52) | LMNAHTTRAB9AHSPB1ALDH1A1 | |
| SCHEMBL12050816 | 0.76 | HSPB1 (0.55) | LMNAHTTRAB9AHSPB1ALDH1A1 | |
| SCHEMBL580833 | 0.76 | CLK1 (0.49) | ROCK1LMNAHTTRAB9AHSPB1 | |
| SCHEMBL31403749 | 0.76 | MAP4K4 (0.51) | ROCK1HTTRAB9AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4025570-A1 | HYDANTOIN DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021043245-A1 | HYDANTOIN DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-11 | — | — | WO | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| EP-1689376-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051366-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | RET, PRKDC, PRKACA | ROCK1 1149/4885LMNA 2847/4885HTT 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.